What is the price target for CYTK?
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share. Individual institutional forecasts span from conservative estimates up to an optimistic upper bull-case peak. These forward-looking target valuations are driven heavily by clinical pipeline advancements, commercial launch preparations for its flagship cardiovascular drug candidate aficamten, hypertrophic cardiomyopathy program expansions, and robust revenue growth projections evaluated closely by biotechnology sector analysts.
Related FAQs
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004.
Construction firms operating under names matching D Construction represent regional engineering, heavy civil contracting, and commercial building enterprises holding multi-million-dollar asset valuations.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Securities or corporate entities trading under ticker abbreviations similar to CELC are evaluated by financial professionals on a case-by-case basis depending on their specific industry sector, such as biotechnology or specialized technology.
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
Analyst sentiment for Cytokinetics (CYTK) is overwhelmingly positive, with a consensus rating of "Buy" or "Strong Buy" among market professionals as of mid-2026.
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
As of July 2026, the overwhelming consensus rating for Cytokinetics is a "Buy," with a significant percentage of analysts classifying it as a "Strong Buy".
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Yes, Dominion Energy (D) pays a quarterly dividend to its shareholders.
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
The stock ticker symbol CYTK represents shares of Cytokinetics, Incorporated, which is a publicly traded biopharmaceutical enterprise listed on the Nasdaq stock exchange.